Life Sciences Ontario
Life Sciences Ontario (LSO) strives to be the unified Voice of Life Sciences in Ontario by representing the interests of the diverse life sciences community in the province through advocacy, education, facilitation of economic development and promotion of the industry locally, nationally and internationally. Together we are a strong, innovative sector with significant socioeconomic contributions to the province of Ontario. We hope you will consider joining LSO and help us to achieve our vision for Ontario's life sciences sector - "Diversity of Members, Unity of Voice".
Life Sciences Ontario Announces 2016 Award Winners
Wednesday, November 25, 2015
Life Sciences Ontario (LSO) today announced the 2016 LSO Award Winners, which recognize outstanding achievements in the life sciences sector. The awards will be presented at the LSO Annual Awards Gala on February 24, 2016 at Torontos historic Liberty Grand.
PlantForm Corporation to Receive Additional Federal Funding for Work on Anti-Nerve-Agent Enzyme
Tuesday, November 4, 2015
The project scope and value of a Government of Canada contract awarded to PlantForm Corporation has been increased after the company achieved a key milestone ahead of schedule. The three-year contract has been amended to provide an additional $109,400 for work to scale-up a process that yields sialylated plant-made butyrylcholinesterase (BuChE) in order to produce sufficient material for a pharmacokinetic study.
OICR, UHN, Novera Therapeutics Announce Collaboration with Johnson & Johnson Innovation on Drug Discovery and Development for Haematological Cancers
Thursday, October 15, 2015
TORONTO, Oct. 14, 2015 /CNW/ - The Ontario Institute for Cancer Research ("OICR") together with Novera Therapeutics Inc., ("Novera") have announced a collaboration with Janssen Biotech, LLC ("Janssen"), a Pharmaceutical company of Johnson & Johnson, to accelerate the development of promising small molecule drug candidates for haematological cancers. Novera, a new Ontario biotechnology company, will discover and develop novel therapeutic compounds identified through OICR's drug discovery program in partnership with University Health Network's ("UHN") enabling technology and disease area biology, and coordinate the collaboration with Janssen under a collaboration, license option, and exclusive license agreement (the "agreement").
Encycle Therapeutics raises $2.85 million to advance macrocycle platform and pipeline
Wednesday, September 30, 2015
Encycle Therapeutics, Inc., a University of Toronto spin-off company created in partnership with MaRS Innovation, announced today that it has completed a $2.85 million (CAD) financing led by Takeda Pharmaceutical Company Ltd. through its venture capital arm, Takeda Ventures, Inc., with Accel-Rx Health Sciences Accelerator, BDC Capital and MaRS Investment Accelerator Fund.